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Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) is a potential anticancer drug since it induces
apoptosis preferentially in malignant but not in normal cells. Not all cancer cells, however, are TRAIL susceptible.
Chemotherapeutic drugs and ionizing radiation have been found to be able to sensitize resistant tumor cells for
TRAIL-induced apoptosis. Since ultraviolet B radiation (UVB) is a potent inducer of apoptosis but exhibits much
less adverse effects, we studied whether UVB sensitizes TRAIL-resistant melanoma cells. Therefore, we analyzed
the TRAIL-sensitive human cell line A-375 in comparison to the resistant cell line IGR-37. Both cell lines showed
expression of the long form of the antiapoptotic FLICE inhibitory protein FLIPL which, however, was partially
cleaved into the 43 kDa form in A-375 cells. In addition, only IGR-37 cells expressed the short splicing variant FLIPS,
which exerts high antiapoptotic activity. Accordingly, transient overexpression of FLIPS rendered A-375 cells
resistant to TRAIL. Upon exposure to low UVB doses, TRAIL-treated IGR-37 cells underwent pronounced apoptosis
and TRAIL sensitivity of A-375 cells was dramatically increased. In both cases, UVB caused an inhibition of flip
expression. This study indicates that (i) the expression level and the processing status of FLIP may play a crucial
role in determining the sensitivity of melanoma cells towards TRAIL and (ii) expression of FLIP is regulated by UVB.
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Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) is a type II membrane protein which belongs to
the tumor necrosis factor (TNF) family of death ligands.
TRAIL was initially found to induce apoptosis in tumor cells
but to spare normal cells (Wiley et al, 1995; Pitti et al, 1996;
Kothny-Wilkes et al, 1998). Because of this selectivity,
TRAIL was handled as an ideal anticancer drug (Walczak
et al, 1999).
Four major receptors for TRAIL have been described.
Although TRAIL binds to all four receptors, only two, TRAIL-
R1 and TRAIL-R2, transduce the death signal and induce
apoptotic cell death (Pan et al, 1996; MacFarlane et al,
1997; Screaton et al, 1997; Sheridan et al, 1997; Walczak
et al, 1997; Wu et al, 1997). The third receptor, TRAIL-R3,
binds TRAIL but due to the lack of the intracellular death
domain is unable to transduce the apoptotic signal (Degli-
Esposti et al, 1997a; MacFarlane et al, 1997; Pan et al, 1997;
Sheridan et al, 1997). TRAIL-R4 carries a cytoplasmic re-
gion lacking most of the death domain which is crucial for
the induction of apoptosis (Degli-Esposti et al, 1997a, b;
Marsters et al, 1997). Thus, TRAIL-R3 and TRAIL-R4 may
act as antagonizing decoy receptors inhibiting TRAIL-me-
diated apoptosis (Degli-Esposti et al, 1997a; MacFarlane
et al, 1997; Pan et al, 1997; Sheridan et al, 1997).
The in vivo efficacy of TRAIL was demonstrated by pre-
clinical studies reporting that TRAIL actively suppresses the
growth of a human mammary adenocarcinoma cell line in a
murine xenotransplant model (Walczak et al, 1999). In ad-
dition, TRAIL-deficient mice exhibit an increased suscepti-
bility to tumor initiation by the chemical carcinogen
methylcholanthrene and reveal an enhanced metastasis
rate (Cretney et al, 2002). With the increasing number of
studies, however, it turned out that not all tumor cells re-
spond to TRAIL. Since transcripts for TRAIL-R3 were initially
detected in many normal human tissues but not in most
cancer lines examined, it was suggested that the expres-
sion of decoy receptors may determine whether cells are
susceptible or resistant to TRAIL (Pan et al, 1997; Sheridan
et al, 1997). Accordingly, it was shown for human melanoma
cells that differential localization and regulation of death and
decoy receptors for TRAIL may account for the differences
in the response to TRAIL (Zhang et al, 2000). There is in-
creasing evidence, however, that cells expressing the decoy
receptors can undergo apoptosis in response to TRAIL as
well (Griffith and Lynch, 1998a).
Intracellular mechanisms may also account for the re-
sistance against TRAIL. This may be either due to the lack
of expression of caspase-8, a crucial upstream caspase in
the TRAIL signalling pathway (Grotzer et al, 2000; Hopkins-
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Donaldson et al, 2000; Eggert et al, 2001; Fulda et al, 2001),
or due to the overexpression of antiapoptotic proteins in-
cluding the FLICE inhibitory protein (FLIP, Griffith et al,
1998b). Two splicing variants of FLIP exist, a 55 kDa long-
form FLIPL and a 28 kDa short-form FLIPS, both of which
interact with the adaptor protein Fas adapter protein with
death domain (FADD) and the proapoptotic procaspase-8
(Boldin et al, 1996), thereby inhibiting death receptor-
induced apoptosis (Nagata, 1997). Upon death receptor ac-
tivation both forms are recruited to the death effector
domain (DED) of FADD, a crucial component of the death-
inducing signalling complex (DISC). There FLIPL either pre-
vents binding and subsequent activation of procaspase-8
(Tschopp et al, 1998) or it heterodimerizes with procaspase-
8, resulting in cleavage of FLIPL into a large (43 kDa) subunit
that remains at the DISC and a small (12 kDa) subunit which
is released (Irmler et al, 1997; Micheau et al, 2002). At the
same time, procaspase-8 is incompletely cleaved into the
p43 and p41 subunits and concominantly the p10 subunit is
released from the complex (Krueger et al, 2001a; Krueger
et al, 2001b). Accordingly, high levels of the 43 kDa trun-
cated form of FLIPL indicate that most of the protecting
FLIP molecules have been cleaved, presumably by ca-
spase-8. FLIPS also interacts with FADD and caspase-8 but
without causing cleavage of caspase-8 (Krueger et al,
2001a). Therefore, previous studies indicated FLIPS to be
the more efficient inhibitor of caspase-8 (Thome et al, 1997;
Kirchhoff et al, 2000; Bin et al, 2002) than FLIPL (Goltsev
et al, 1997; Han et al, 1997; Inohara et al, 1997; Shu et al,
1997).
Since chemotherapeutic drugs induce apoptosis and
therefore may share common signalling pathways inducing
apoptotic cell death, it was investigated whether anticancer
drugs and TRAIL can act in a synergistic manner. In fact, it
was reported that chemotherapeutic drugs augment the
cytotoxic effect of TRAIL in TRAIL-sensitive tumor cell lines
(Gliniak and Le, 1999; Keane et al, 1999; Gibson et al, 2000;
Nagane et al, 2000; Frese et al, 2002). Even more impor-
tantly, after pre-treatment with particular chemotherapeutic
drugs originally TRAIL-resistant tumor cell lines became
highly susceptible to TRAIL treatment (Dejosez et al, 2000;
Yamanaka et al, 2000; Lacour et al, 2001; Mizutani et al,
2001; Evdokiou et al, 2002). In addition, ionizing radiation
can sensitize breast cancer cells and Jurkat clones to
TRAIL-induced apoptosis (Chinnaiyan et al, 2000; Kim et al,
2001). Although the mechanisms by which chemothera-
peutics and ionizing radiation sensitize resistant cells to
TRAIL remain to be clarified, such combinations may be of
high potential value for the development of future thera-
peutic anti-cancer strategies.
Ultraviolet B radiation (UVB) is a potent inducer of
apoptosis. In the in vivo situation UVB induces apoptosis
perferentially in keratinocytes, which are the major target
cells for solar radiation by virtue of their anatomic location.
UVB-damaged keratinocytes appear as sunburn cells within
the epidermis (Murphy et al, 2001). UVB-mediated nuclear
DNA damage has been recognized to be the major molec-
ular trigger for the induction of apoptosis (Kulms et al, 1999).
In addition, death receptors like Fas/CD95 appear to be
involved in UVB-induced apoptosis, because UVB exhibits
the capacity to directly activate death receptors without the
need of the respective death ligand (Rehemtulla et al, 1997;
Aragane et al, 1998). Both pathways were shown to con-
tribute independently to the complete apoptotic response of
the cell to UVB (Kulms et al, 1999). Recently, reactive ox-
ygen species generated by UVB were identified to play an
additional role in execution of apoptotic cell death, repre-
senting a third pathway to be involved (Kulms et al, 2002).
Taken together, UVB-induced apoptosis is a highly complex
process in which several signalling pathways appear to be
essential but independent from each other.
Since the potential side-effects of short-term UVB ex-
posure are much less severe than those of chemothera-
peutics or even ionizing radiation, we were interested to
clarify whether UVB is suitable to switch tumor cells from a
TRAIL-resistant into a sensitive state. Here, we provide ev-
idence that upon exposure to low-dose UVB, TRAIL-resist-
ant human melanoma cell lines become highly susceptible
to the cytotoxic effect of TRAIL. In addition, UVB enhances
TRAIL susceptibility of sensitive melanoma cells in a highly
synergistic manner. In both cases, UVB-mediated suppres-
sion of flip expression seems to play a crucial role in altering
TRAIL sensitivity. The combination of UVB phototherapy
and the application of TRAIL may represent a promising
treatment modality, in particular for advanced cutaneous T
cell lymphoma and disseminated cutaneous metastasis by
malignant melanoma.
Results
Normal human melanocytes are resistant against
TRAIL-induced apoptosis First we analyzed the suscep-
tibility of normal human melanocytes towards TRAIL-in-
duced apoptosis. Human melanocytes were subjected to
100 ng per mL TRAIL for 16 h and the apoptosis rate was
determined utilizing a cell death detection ELISA. Human
melanocytes were resistant against TRAIL (Fig 1), whereas
Figure1
Human melanocytes are resistant against TRAIL-induced apopto-
sis. Primary human melanocytes and A-375 cells were treated with
TRAIL (100 ng per mL). After an incubation period of 16 h, apoptosis
was quantified by a cell death detection ELISA. Enrichment factor was
used as a parameter of apoptosis and is given as the mean  SD of
triplicates. Data presented show one representative of three independ-
ently performed experiments.
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the human melanoma cell line A-375 underwent apoptosis
upon exposure to the same concentration of TRAIL.
Human melanoma cells show different susceptibility to
TRAIL In order to analyze the sensitivity of different me-
lanoma cells to TRAIL, eight human melanoma cell lines
(A-375, G-361, IGR-37, IPC-298, SK-Mel-30, WM-9, WM-35,
WM-902B) were stimulated with increasing doses of re-
combinant human TRAIL ranging from 25 to 100 ng per mL.
Sixteen hours later, induction of apoptosis was evaluated by
using a cell death detection ELISA. Only three of eight cell
lines tested responded to TRAIL stimulation (Table I). Al-
though A-375, G-361, and WM-35 cells were highly sensi-
tive to TRAIL in a concentration-dependent manner, IGR-37,
IPC-298, SK-Mel-30, WM-9, and WM-902B cells appeared
to be highly resistant against TRAIL-induced apoptosis.
TRAIL receptor expression is not responsible for the
different susceptibility towards TRAIL treatment To de-
termine whether the different sensitivity of the melanoma
cell lines is due to a different expression pattern of TRAIL
receptors, FACS analysis was performed. As demonstrated
in Fig 2, all cell lines expressed either TRAIL-R1 or TRAIL-
R2, or both, irrespective of whether they were resistant or
sensitive to TRAIL-induced apoptosis. In fact, the expres-
sion level of the TRAIL receptors varied throughout the dif-
ferent cell types but no obvious correlation between TRAIL-
R1 and -R2 expression and the susceptibility to TRAIL could
be revealed. In addition, neither of the cell types investi-
gated expressed the antagonistic receptors TRAIL-R3 and
-R4 (Fig 2), indicating that the different sensitivity does not
correlate with the expression pattern of the receptors.
IGR-37 cells are resistant even to very high doses of
TRAIL To further investigate the mechanisms that confer
susceptibility to TRAIL, we selected a sensitive (A-375) and
a resistant (IGR-37) cell line for detailed analyses. In order to
determine whether resistant cells may respond to higher
doses of TRAIL, both cell lines were stimulated with TRAIL
up to 1000 ng per mL and analyzed in a cell death detection
ELISA after 16 h. The sensitive A-375 cells showed a max-
imum apoptotic response upon treatment with 100 ng per
mL TRAIL, which could not be further enhanced by higher
doses, whereas IGR-37 cells remained resistant throughout
the whole dose range supplied (Fig 3).
Different expression patterns of the inhibitory FLIP
protein may contribute to the cellular response to
TRAIL The major signaling pathway of TRAIL acts through
formation of the DISC and activation of caspase-8 (Bodmer
et al, 2000; Sprick et al, 2000). Since it was reported that the
resistance against TRAIL may be due to a lack of the ex-
pression of caspase-8 (Grotzer et al, 2000; Hopkins-Don-
aldson et al, 2000), the existence of the different DISC
components in melanoma cells was determined by western
blot analysis. TRAIL-sensitive A-375 and -resistant IGR-37
melanoma cells expressed both FADD and caspase-8 at
equal levels (Fig 4A), indicating identical conditions to
transduce the apoptotic signal for both cell lines. Whereas
both cell lines expressed the 55 kDa FLIPL, only the TRAIL-
resistant IGR-37 cells additionally expressed the 28 kDa
FLIPS, which had been described to be a stronger inhibitor
of caspase-8 activation than FLIPL (Fig 4A). Furthermore,
only the sensitive A-375 cells expressed the 43 kDa form of
FLIPL which appears to be a proteolytic cleavage product of
FLIPL. This implies that even in unstimulated A-375 cells, a
low basic level of caspase activation may exist, resulting in
pre-apoptotic FLIPL truncation. This may account for the
high sensitivity of A-375 cells towards TRAIL. Accordingly,
activation of caspase-8 which results in cleavage of the 55/
57 kDa forms into 42/44 kDa and subsequently into 25 kDa
fragments, could be documented in a time-dependent
manner upon TRAIL stimulation only in sensitive A-375 but
not in resistant IGR-37 cells (Fig 4B). Taken together, the
data so far suggest that TRAIL resistance may be related to
different expression levels of FLIPS and to pre-apoptotic
processing of FLIPL, presumably by caspase-8.
Transfection with FLIPS renders sensitive A-375 cells
resistant to TRAIL-induced apoptosis To determine
whether expression of FLIPS in IGR-37 cells is responsible
for mediation of TRAIL resistance and whether consequent-
ly A-375 sensitivity towards TRAIL is due to the lack of
FLIPS expression, we transiently transfected A-375 cells
with a plasmid expressing FLIPS under the control of a CMV
promoter. Expression of FLIPS conferred TRAIL resistance
in A-375 cells (Fig 5). This indicates that expression of FLIPS
may play a major role in inhibiting TRAIL-mediated apopto-
tic signal transduction and that FLIPS might be the major
inhibitor of apoptosis in melanoma cells compared to FLIPL.
Caspase inhibitors differentially affect TRAIL-induced
apoptosis Caspase-8 is the most proximal initiator ca-
spase and responsible to mediate TRAIL-induced apoptotic
Table I. TRAIL sensitivity of different melanoma cells lines
Cell typea
Apoptotic responseb
Statusc
TRAIL
25 ng
per mL
50 ng
per mL
100 ng
per mL
A-375    S
G361 Ø   S
IGR-37 Ø Ø Ø R
IPC-298 Ø Ø  R
Skmel Ø Ø Ø R
WM-9 Ø Ø Ø R
WM-35    S
WM-902B Ø Ø Ø R
aThe melanoma cell lines were treated with either 25, 50, or 100 ng per
mL TRAIL. 16 h later cell death detection ELISA was performed and the
enrichment factor determined as a measure for apoptotic response.
bEach cell line was tested three times with each TRAIL concentration
and the average enrichment factor was statistically determined. Ø, en-
richment factor o2; , enrichment factor 42; , enrichment factor 45;
, enrichment factor 410. An enrichment factor of 2 corresponds to an
increase of apoptotic cells of 5%, as determined by Annexin V staining
followed by FACS analysis.
cCells were categorized into TRAIL-sensitive (S) or -resistant (R) lines.
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signal transduction (Bodmer et al, 2000). Additionally, ca-
spase-8 was described to interact with its inhibitor FLIP
within the DISC, indicating that pre-apoptotic FLIP cleavage
might result from enhanced caspase-8 activity. To address
this issue, we selectively inhibited caspase-8 by pre-treat-
ment of A-375 cells with the specific inhibitor zIETD in
comparison to inhibition of another initiator caspase, ca-
spase-9, by zLEHD. TRAIL-induced apoptosis was com-
pletely inhibited by zIETD, comparable to the inhibition by
the pan-caspase inhibitor zVAD (Fig 6A). In contrast,
zLEHD-mediated caspase-9 inhibition only partially re-
duced TRAIL-induced apoptosis. This indicates that ca-
pase-8 activation plays the key role in TRAIL-mediated
initiation of apoptosis. Based on the findings demonstrated
in Fig 4A, we postulated that caspase-8 might also be re-
sponsible for the constitutive proteolytic cleavage of FLIPL,
thereby rendering cells TRAIL susceptible. Thus, the effect
of zIETD on FLIP processing was determined. zIETD, how-
ever, did not prevent FLIP cleavage. Interestingly, western
blot analysis indicated that proteolytic truncation of FLIPL
seems to be independent of any caspase, since culturing
Figure 2
Analysis of TRAIL receptor expression. Cell surface expression of TRAIL receptors was determined by FACS analysis. Cells were incubated with
specific antibodies against the different TRAIL receptors or with the respective isotype control. Secondary antibodies were conjugated with FITC.
The histograms show the level of receptor-based fluorescence: TRAIL-R1 (open red), TRAIL-R2 (open blue) in the corresponding left histogram and
TRAIL-R3 (open yellow), TRAIL-R4 (open green) in the right histogram, in relation to isotype control (solid filled gray histograms). x-axis: TRAIL
receptor expression on cell surface based on FITC fluorescence intensity (FL1: 10–104 arbitrary units), y-axis: relative number of cells (20,000 cells
were analyzed).
Figure 3
IGR-37 cells are resistant even to high TRAIL concentrations. Cells
from the resistant melanoma cell line IGR-37 and the sensitive me-
lanoma cell line A-375 were treated with doses of TRAIL up to 1000 ng
per mL. After 16 h, apoptosis was determined using a cell death de-
tection ELISA. The rate of apoptosis is reflected by the enrichment of
nucleosomes in the cytoplasm shown on the y-axis (mean  SD of
triplicate samples). Data presented show one representative of three
independently performed experiments.
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A-375 cells in medium supplemented with 20 mM of each
caspase inhibitor, including zVAD, for three days could not
inhibit or even reduce FLIPL cleavage (Fig 6B). This implies
that though being the major caspase in triggering TRAIL-
induced apoptosis, caspase-8 does not seem to be re-
sponsible for pre-apoptotic FLIPL truncation.
Exposure to UVB renders TRAIL-resistant melanoma
cells highly susceptible to TRAIL Next, we were inter-
ested to find out whether UVB may sensitize cells to TRAIL-
induced apoptosis, as demonstrated previously for other
apoptotic stimuli (ionizing radiation or chemotherapeutic
drugs). Exposure of A-375 cells to 25 ng per mL TRAIL
caused moderate apoptosis (Fig 7). An even lower rate of
apoptosis was observed when cells were exposed to 200 J
per m2 UVB. When both stimuli were combined, however,
cell death was dramatically induced, revealing a pro-
nounced synergistic effect. Even more important was the
combinatorial effect on resistant IGR-37 cells. Exposure to
even 50 ng per mL TRAIL or UVB (200 J per m2) did not
induce apoptosis, but the combination of both stimuli re-
sulted in pronounced apoptosis. Similar results were ob-
tained for the other TRAIL-resistant melanoma cell lines
IPC-298, Sk-Mel-30, WM-9, WM-902B (data not shown).
FACS analysis revealed that the sensitization effect
caused by UVB was not due to the induction of the ex-
pression of the signalling receptors TRAIL-R1 and TRAIL-R2
(data not shown). Since the data presented above suggest-
ed a crucial role of FLIP in mediating resistance to TRAIL,
the effect of UVB on FLIP expression was determined by
Figure4
Western-blot analysis of DISC forming proteins.
(A) 30–50 mg protein of whole-cell extracts from un-
treated A-375 and IGR-37 cells, respectively, were
analyzed on 10% SDS-PAGE followed by immuno-
blotting with antibodies directed against FADD, ca-
spase-8 and FLIP, respectively. Equal loading was
monitored by reprobing membranes with an anti-a-
tubulin antibody. (B) Sensitive A-375 and resistant
IGR-37 cells were stimulated with 50 ng per mL of
recombinant TRAIL. Caspase-8 activation was doc-
umented by subjecting protein extracts at the dif-
ferent time points indicated to western blot analysis
using an antibody directed against caspase-8. No
caspase-8 cleavage could be detected in extracts
from IGR-37 cells.
Figure 5
Expression of FLIPS mediates resistance against TRAIL-induced
apoptosis in A-375 cells. A-375 cells were transiently mock trans-
fected or transfected with a plasmid expressing FLIPS under control of
a CMV promoter. 30 h later cells were treated with 25 ng per mL of
recombinant TRAIL. 16 h later apoptosis was measured using a cell
death detection ELISA. The rate of apoptosis is reflected by the en-
richment of nucleosomes in the cytoplasm shown on the y-axis
(mean  SD of triplicate samples), showing one representative of three
independently performed experiments.
Figure6
Caspase inhibitors differentially affect TRAIL sensitivity of A-375
cells towards TRAIL-induced apoptosis. (A) A-375 cells were pre-
treated with caspase inhibitors zIETD, zLEHD, or zVAD (20 mM each) for
1 h followed by stimulation with 50 ng per mL of recombinant TRAIL.
After 16 h, apoptosis was quantified by a cell death detection ELISA.
The rate of apoptosis is reflected by the enrichment of nucleosomes in
the cytoplasm shown on the y-axis (mean  SD of triplicate samples).
Data presented show one representative out of three independently
performed experiments. (B) A-375 cells were cultured with medium
containing 20 mM of the respective caspase inhibitors zIETD, zLEHD
and zVAD for 3 days. Protein extracts of unstimulated cells were analy-
zed in Western blot analysis on a 12% SDS-PAGE with an antibody
directed against FLIP.
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semiquantitative PCR analysis. The constitutive expression
level of ﬂip appeared to be higher in the TRAIL-resistant
cells than in the sensitive cells (Fig 8A). Furthermore, PCR
analysis revealed that exposure to 200 J per m2 UVB re-
sulted in a complete inhibition of ﬂip expression in sensitive
A-375 cells. Likewise, UVB caused a significant reduction of
ﬂip expression in IGR-37 cells. Correspondingly, UVB-me-
diated downregulation of FLIP at the protein level could be
documented for both cell lines (Fig 8B). This indicates that
UVB might enhance TRAIL sensitivity by downregulating
FLIP expression, and that this mechanism may be respon-
sible for switching TRAIL-resistant into sensitive cells.
Taken together, the expression level of FLIP and the pre-
apoptotic truncation of FLIPL p55 into p43 seem to crucially
determine the susceptibility of melanoma cells towards
TRAIL-induced apoptosis. In addition, FLIP expression ap-
pears to be regulated by UVB radiation.
Discussion
To analyze the mechanisms determining TRAIL-resistance
in melanoma cells, we compared 3 TRAIL-sensitive with
5 TRAIL-resistant melanoma cell lines with regard to
TRAIL receptor distribution. No correlation between TRAIL
suceptibility and the expression pattern of the signalling re-
ceptors TRAIL-R1 and -R2 could be detected, whereas
none of the cell lines tested expressed any of the decoy
receptors. In addition, we could not reveal any significant
difference in the expression of the crucial signalling pro-
teins. In contrast, we observed an obvious difference in the
protein levels of the antiapoptotic protein FLIP between the
two cell lines analyzed in more detail. Resistant IGR-37 cells
and sensitive A-375 cells expressed similar levels of FLIPL
(p55), whereas only resistant IGR-37 cells additionally ex-
pressed considerable amounts of FLIPS (p28). Since no
cross-activation of caspase-8 occurs upon heterodimerizat-
ion with FLIPS but only with FLIPL, FLIPS is considered to be
a more effective caspase inhibitor than FLIPL. Several pre-
vious studies revealed that FLIPL under certain conditions
may even promote cell death. Inohara et al (1997) demon-
strated overexpression of CLARP, a FLIPL homologue, to
augment the killing ability of caspase-8 and FADD in ma-
malian cells. Also, overexpression of the FLIPL homologue
Casper was shown to induce apoptosis in HtTA cells (Shu
et al, 1997). Furthermore, Goltsev et al (1997) demonstrated
CASH, also a FLIPL homologue, to either attenuate and/or
initiate CD95-mediated apoptosis in a cell-type-dependent
fashion. Conclusively, additional FLIPS expression may ac-
count for TRAIL resistance. Likewise, upregulation of FLIPS
was shown to block apoptosis in T cells (Kirchhoff et al,
2000). In accordance with the observations described
above, overexpression of FLIPS rendered sensitive A-375
cells resistant to TRAIL-induced apoptosis.
Furthermore, FLIPL p55 was shown to be partially
cleaved into p43 prior to induction of apoptosis by TRAIL
in sensitive A-375, but not in resistant IGR-37 cells. Usual-
ly, recruitment of caspase-8 and FLIP to the DISC upon
death receptor activation results in caspase-8-dependent
processing of FLIPL into the p43 truncated form (Scaffidi
et al, 1999). The detection of p43 in A-375 cells indicates
FLIPL truncation even before death receptor activation and
DISC formation, which may contribute to the sensitivity to
TRAIL. Thus, we assumed that spontaneous FLIP cleavage
may be mediated by caspase-8. This does not seem to be
the case, however, since FLIP cleavage could not be inhib-
ited by zIETD. Since the pan-caspase inhibitor zVAD did
Figure 7
Exposure to low-dose UVB renders TRAIL-resistant melanoma
cells highly susceptible towards TRAIL. Sensitive (A-375) and re-
sistant (IGR-37) melanoma cells were either left untreated or irradiated
with low dose UVB (200 J per m2) in the absence or presence of 25 ng
per mL (A-375) or 50 ng per mL (IGR-37) of TRAIL. After an incubation
period of 16 h the apoptosis rate was determineded by a cell death
detection ELISA. Enrichment factor was used as a parameter of
apoptosis and is given as the mean  SD of triplicates. Data presented
show one representative of three independently performed experi-
ments.
Figure 8
UVB suppresses FLIP expression. (A) TRAIL-sensitive (A-375) as well
as TRAIL-resistant (IGR-37) melanoma cells were either left untreated
or exposed to 200 J per m2 UVB. Total RNA was extracted 7 h after
treatment and RT-PCR was performed using primer pairs specific for
flip and b-actin, respectively. A flip-specific 228 bp fragment and a b-
actin-specific 860 bp fragment were detected on a 1.2 % agarose gel.
(B) Eight hours after the identical treatment proteins were extracted and
analyzed by Western-blot analysis on 12% SDS-PAGE with an antibody
directed against FLIP. Equal loading was monitored by reprobing the
membrane with an anti-a-tubulin antibody.
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also not affect FLIP truncation, this phenomenon may be
caspase independent. Supporting the hypothesis of ca-
spase-independent FLIP processing, Scaffidi et al (1999)
observed cleavage of overexpressed FLIP in BJAB cells
very shortly after CD95 activation when no caspase-8 ac-
tivation was detectable. In addition, very shortly after CD95
stimulation only the truncated p43 from of FLIPL was de-
tectable in the highly CD95L-sensitive murine A20 B-cells
which harbor low cellular FLIP levels (Micheau et al, 2001).
Thus, it was speculated that the entire FLIP pool had been
used up from caspase-/FLIP heterodimers leaving residual
caspase-8 unprotected which results in caspase-8 ho-
modimerizatrion, autoactivation, and cell death. In our sys-
tem, we could not detect caspase-8/FLIP heterodimers
(data not shown), which could be due to the fact that these
heterodimers are either not formed or not stable. Although
the final mechanism that underlies pre-apoptotic process-
ing of FLIPL remains to be determined, it may serve as an
indicator for cells that are very sensitive towards death lig-
and-induced apoptosis.
Chemotherapeutic drugs cannot only augment the sen-
sitivity but also convert TRAIL-resistant into sensitive tumor
cells (Dejosez et al, 2000; Evdokiou et al, 2002). The mech-
anism by which chemotherapeutic drugs augment and
sensitize cells to TRAIL-mediated toxicity remains to be
determined. Studying the effect of chemotherapeutic drugs
on the effect of TRAIL in non-small cell lung cancer cell
lines, Frese et al (2002) observed that a synergistic effect
can be achieved by camptothecin, cisplatin, doxorubicin,
and 5-flurorouracil but not with paclitaxel. Whereas the
other drugs represent DNA-damaging agents, paclitaxel
exerts its apoptotic effects through stabilization of the
microtubule system. Therefore, the authors suggested
that DNA damage but not mitotic arrest is required for aug-
menting TRAIL-induced apoptosis.
Accordingly, ionizing radiation which damages the DNA
was found to synergize with TRAIL in the regression of
established human breast cancer xenografts in mice
(Chinnaiyan et al, 2000). Belka et al (2001) observed that
overexpression of the antiapoptotic protein Bcl-2 inhibits
apoptosis induced by ionizing radiation but not by TRAIL
Pre-treatment with TRAIL rendered Bcl-2 overexpressing
cells highly susceptible to TRAIL, suggesting that TRAIL can
sensitize resistant cells to irradiation-induced apoptosis.
Vice versa, ionizing radiation was found to overcome un-
responsiveness to TRAIL in TRAIL-resistant Jurkat clones
(Kim et al, 2001).
Here, we show that UVB also exhibits the capacity to
sensitize resistant cells to TRAIL-induced apoptosis. The
rationale to utilize UVB was 2-fold. Firstly, like ionizing ra-
diation and chemotherapeutic drugs UVB induces DNA
damage, though the photolesions in nuclear DNA induced
by UVB are different in nature from those induced by ion-
izing radiation and chemotherapeutic drugs. Secondly, the
side-effects of UVB even upon long-term application are
much less severe than those of ionizing radiation and of
chemotherapeutics. Low-dose UVB converted TRAIL-re-
sistant melanoma cells into a highly sensitive state and
augmented TRAIL toxicity in a highly synergistic manner in
the sensitive melanoma cell line. Chemotherapeutic drugs
appear to augment the cytotoxic effect of TRAIL via upreg-
ulation of the signalling receptors TRAIL-R1 and TRAIL-R2
(Gibson et al, 2000, Nagane et al, 2000). UVB, however, did
not alter the expression of TRAIL receptors on melanoma
cells as demonstrated by FACS analysis (data not shown).
In contrast, sensitization seemed to be associated with a
downregulation of ﬂip mRNA and consequently FLIP protein
levels by UVB. PCR analysis revealed that the constitutive
expression level of ﬂip is higher in resistant IGR-37 cells
than in sensitive A-375 cells. Since the overall protein levels
of FLIP were similar in IGR-37 and A-375 cells, this phe-
nomenon might account for higher FLIP turnover rates in
IGR-37 cells, which consequently supports the concept
of FLIP-mediated resistance. Additionally, the fact that ﬂip
becomes downregulated upon UVB exposure in both cell
lines argues for the important role of FLIP in mediating
TRAIL resistance, because resistant cells become sensitive
towards TRAIL-induced apoptosis and susceptibility of
sensitive cells gets even enhanced. In summary, FLIP
expression levels together with the pre-apoptotic process-
ing status seem to be the crucial components in the deci-
sion whether a melanoma cell is sensitive or resistant to
TRAIL treatment.
Elucidation of the mechanisms by which UVB sensitizes
resistant cells to the cytotoxic effect of TRAIL is of primary
importance, because the combination of phototherapy and
TRAIL may be of potential practical value for the treatment
of malignancies, in particular of advanced cutaneous T cell
lymphomas and disseminated cutaneous metastasis of ma-
lignant melanoma. Phototherapy is the treatment of choice
for early stage cutaneous T cell lymphoma, however, is only
of limited value in advanced stages, in particular the tumor
stage. On the other hand, cutaneous T cell lymphoma
tumors are quite resistant against chemotherapy. Ionizing
radiation can induce remission of tumors but does not pre-
vent relapses. Therefore, advanced stage cutaneous T cell
lymphoma is still associated with a poor prognosis in terms
of long-term survival. Another therapeutic challenge is dis-
seminated cutaneous metastasis by malignant melanoma.
Based on our findings, one may surmise that phototherapy
may be a suitable tool to convert TRAIL-resistant cutaneous
melanoma metastasis into a susceptible state. Since in
contrast to ionizing radiation, UVB can be applied as fre-
quently as necessary, it is tempting to speculate that the
combination of phototherapy with TRAIL might be of ther-
apeutic benefit for this type of malignancies.
Materials and Methods
Cells and reagents The human melanoma cell lines were either
obtained from DSMZ (German Collection of Microorganisms and
Cell Culture, Braunschweig, Germany), or from the American Type
Culture Collection (ATCC). Normal human epidermal melanocytes
(NHEM) derived from human foreskin were obtained from Promo-
Cell (Heidelberg, Germany). Melanoma cells were maintained in
RPMI 1640 medium supplemented with 10% FCS (vol/vol) and
0.5% Cibrobay (vol/vol) at a density of 5  105 cells per mL in a
humidified atmosphere of 5% CO2 at 371C. Six hours prior to
stimulation cells were kept in colorless RPMI medium containing
5% FCS. UVB irradiation was performed using a bank of six flu-
orescent bulbs (TL12, Philips, Eindhoven, The Netherlands), which
emit most of the energy within the UVB range (290–320 nm) with an
emission peak at 313 nm. Unless otherwise stated, a dose of 200 J
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per m2 was applied throughout the study since this dose did not
alter cell viability by itself.
Recombinant human TRAIL protein was obtained from Im-
munex (Seattle, Washington). This recombinant protein was N-ter-
minally fused to a leucin zipper motif (lzTRAIL) in order to
constitutively build the trimerized active form (Walczak et al, 1997).
Activation of caspases was blocked by pre-incubating cells
with 20 mM of the respective inhibitors for caspase-8 (zIETD), ca-
spase-9 (zLEHD) and ICE-proteases (zVAD).
FLIPS expression plasmid (pCR3.V62-Met-Flag-FLIPS) and
the corresponding empty vector were kindly provided by Ju¨rg
Tschopp, Department of Biochemistry, University of Lausanne,
Switzerland.
Determination of cell death Sixteen hours after stimulation cells
were detached from dishes, and apoptosis was measured by a cell
death detection ELISA (Roche Diagnostics GmbH, Mannheim,
Germany). The enrichment of mono- and oligonucleosomes re-
leased into the cytoplasm of cell lysates was detected by bioti-
nylated anti-histone- and peroxidase-coupled anti-DNA-antibodies
and was calculated as follows: absorbance of sample cells/ab-
sorbance of control cells. Unless otherwise stated, this factor was
used as a parameter of apoptosis and is given as the mean  SD
of triplicates, showing one representative of three independently
performed experiments.
Western blot analysis Cells were detached with trypsin, washed
twice in PBS and lysed in lysis buffer (50 mM HEPES, pH 7.5; 150
mM NaCl; 10% glycerol; 1% Triton-X-100; 1.5 mM MgCl2; 1 mM
EGTA; 100 mM NaF; 10 mM pyrophosphate, 0.01% NaN3 and
complete protease inhibitor coktail, Roche Diagnostics GmbH) for
15 min on ice. After denaturation equal amounts of protein were
separated on a 10%–13% standard SDS-PAGE and transferred to
a nitrocellulose membrane by electroblotting. The following pri-
mary antibodies were used for immunodetection: rabbit polyclonal
anti-human caspase-8 antibody (Ab-4; Biocarta, Hamburg, Ger-
many), rabbit polyclonal anti-human I-Flice antibody (BD-Pharmin-
gen, San Diego, California), mouse monoclonal anti-human FADD
antibody (clone A66-2; BD-Pharmingen), Secondary antibodies
were conjugated to horseradish peroxidase (Amersham, Bucking-
hamshire, UK). Bands were visualized by applying a chemilu-
minescense detection system (SuperSignal, PIERCE Biotech-
nology, Rockford, Illinois).
Flowcytometry analysis Cells were carefully removed from cul-
ture dishes by acutase treatment, washed twice with PBS and
incubated with the first antibody (1 mg per mL in PBS supple-
mented with 2% FCS) or an appropriate isotype control antibody
for at least 1 h on ice. The following monoclonal mouse antibodies
against human TRAIL receptors were provided from Immunex:
anti-TRAIL-R1 antibody (M271, IgG2a), anti-TRAIL-R2 (M413), anti-
TRAIL-R3 antibody (M430) and anti-TRAIL-R4 (M445, IgG1). Sub-
sequently, cells were washed twice with PBS plus 2% FCS and
incubated with the secondary goat-anti-mouse antibody conjugat-
ed to FITC. FACS analysis was performed using an EPICS XL-MCL
flow cytometer (Coulter, Miami, Florida). Excitation wavelength
used for FITC was 488 nm, the emitted green fluorescence (lmax
520 nm) was detected using (FL1) band-pass filter. 20,000 cells
were analyzed for each sample. Data analysis was performed by
using the WINMDI 2.8 software program (Flow Cytometry Core
Facility, Scripps Research Institute, La Jolla, California).
Transfection experiments KB cells (8  106) were washed once
with PBS and resuspended in 800 mL of ice-cold transfection buffer
(140 mM NaCl; 5 mM KCl; 0.7 mM Na2HPO4; 6mM glucose; 0.1
mM b-ME, 20 mM HEPES, pH 7.0) containing 1.25% DMSO. Cells
were electroporated with 25 mg of the plasmid pCR3-FLIPS or the
empty vector according to the method described by Melkonyan
et al (1996). Transfection efficacy of cells cotransfected with a
plasmid encoding b-galactosidase (pCMV-bgal; Stratagene, La
Jolla, California) was determined 30 h later by staining cells with
X-gal (100 mg per mL) in 5 mM potassium ferricyanide, 5 mM
potassium ferrocyanide, and 1 mM MgCl2 in PBS. Transfection
efficiency ranged from 30 to 50%.
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